Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析

OBJECTIVE: To observe the clinical efficacy and side effects of brentuximab vedotin (BV) plus chlormethine hydrochloride (CH) in patients with relapsed and refractory Hodgkin lymphoma (HL) after failure with BV alone. METHODS: From March, 2014 to December, 2014, 6 patients who failed with BV monotherapy were enrolled in this study. The chemotherapy regimen consisted of BV (1.2–1.8 mg/kg, iv. gtt, d1) and CH (6 mg/m(2), iv. gtt, d1) was given for 3 weeks as one course, and all patients received about 3–8 courses of chemotherapy, with an median of 4 courses. Clinical efficacy and adverse events were assessed and observed by radiographic examination and serological detection. RESULTS: Among 6 patients, the overall response rate was 100% with 2 complete remissionand 4 partial remission. The main adverse events were grade Ⅰ (2 patients) and Ⅳ (2 patients) bone marrow depression, grade Ⅱ (2 patients) gastrointestinal reaction, grade Ⅰ (1 patient) increase of transaminase and myocardial enzyme and grade I (1 patient) mouth ulcers. CONCLUSION: The combination of BV and CH in the treatment of relapsed and refractory HL after failure with BV alone was high effective and the toxicities were well tolerable.